Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Alpha Cognition Inc ACOG

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.


NDAQ:ACOG - Post by User

Post by waves1on Oct 22, 2021 5:45pm
104 Views
Post# 34039387

Informative $ACOG CEO interview

Informative $ACOG CEO interview
Found a great interview with the CEO of Alpha Cognition Inc. ( $ACOG $ACOG.v $ACOGF) from last month - super informative regarding the upcoming trial, as well as their additional pipeline projects. 
 
ALPHA-1062 compound working towards approval for mild to moderate Alzheimer's 
  • Unique to competitors by focusing on the treatment of the symptoms that patients suffer from, rather than focusing on "stopping the disease" like other competitors are trying to do
  • Treatment is for first-line therapy to ameliorate the symptoms
  • Pivotal trial in Q4 was approved by the FDA; Will be completed in Q1 of 2022 
 
Three additional pipeline programs
  1. Path to approval for moderate to severe Alzheimers with opportunity to compete from diagnosis to end of life
  2. Early stage mild traumatic brain injury
  3. Early stage gene therapy program for ALS also starting in Q4 of 2021 with results expected in Q1 of 2022
<< Previous
Bullboard Posts
Next >>